News und Analysen
3 High-Yield Dividend Stocks I Can't Wait to Buy to Boost My Passive Income
I'm about to get a big cash infusion in my portfolio. Last year, private equity giant Blackstone agreed to buy one of my holdings, Retail Opportunity Investments Corp., in an all-cash deal. That
Biogen (BIIB) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
Biogen (NASDAQ: BIIB)Q4 2024 Earnings CallFeb 12, 2025, 8:30 a.m. ET
Operator
Source Fool.com
Vertex: Strong Sales, Stronger Pipeline
Here's our initial take on Vertex Pharmaceuticals' (NASDAQ: VRTX) fourth-quarter financial report.
Vertex reported solid fourth-quarter numbers throughout its business. While the company's earnings
Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
Vertex Pharmaceuticals (NASDAQ: VRTX)Q4 2024 Earnings CallFeb 10, 2025, 4:30 p.m. ET
Operator
Source Fool.com
Vertex's Revenue Surges but EPS Slips
Vertex Pharmaceuticals(NASDAQ:VRTX), known for its innovative treatments, reported its fourth-quarter earnings on Feb. 10. The company's revenue increased significantly to $2.91 billion, which was
Why Illumina Stock Got Mashed on Monday
On Monday, for the second time in as many business days, Illumina (NASDAQ: ILMN) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader
3 Fabulous Dividend Stocks to Buy in February
February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks
Is Now a Good Time to Buy the Dip on Pfizer?
The past three years have been difficult for Pfizer (NYSE: PFE). The pharmaceutical giant's financial results worsened substantially as its coronavirus-related tailwind came to a screeching halt
These 2 Dividend Stocks Are Absolute Bargains Right Now
Dividend stocks are great for many reasons, not least because any company that can sustain growing payouts for a long time likely has a strong underlying business. It's even better to invest in
Why Illumina Stock Is Sinking Today
Shares of Illumina (NASDAQ: ILMN) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m. ET. At that time, the S&P
Value-Based Care Simplifies Healthcare for Patients and Clinicians, New Report Finds
Value-based care results in patients spending more time with their primary care clinician, less time in the hospital, and more frequent preventive care, based on research released today by leading
Amgen (AMGN) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
Amgen (NASDAQ: AMGN)Q4 2024 Earnings CallFeb 04, 2025, 4:30 p.m. ET
Operator
Source Fool.com
Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday
News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter
Why Illumina Stock Plummeted Today
Genomic sequencing specialist Illumina (NASDAQ: ILMN) was something of a victim in the U.S.-China trade spat on Tuesday. The government of the sprawling Asian nation placed the U.S. company on a
Amgen Surpasses Q4 Earnings Forecasts
Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS of
Pfizer (PFE) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
Pfizer (NYSE: PFE)Q4 2024 Earnings CallFeb 04, 2025, 10:30 a.m. ET
Operator
Source Fool.com
Centene (CNC) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
Centene (NYSE: CNC)Q4 2024 Earnings CallFeb 04, 2025, 8:30 a.m. ET
Operator
Source Fool.com
Pfizer Beats Q4 Revenue, EPS Estimates
Pharmaceuticals giant Pfizer (NYSE:PFE) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. The company reported an adjusted earnings
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in
3 Magnificent Stocks to Buy and Hold Forever
Some people are fair-weather friends; others are lifelong. It's a similar story with stocks. Some you might hold only temporarily, while others you own for decades.
Three Fool.com contributors have
2 Unstoppable Dividend Stocks That Will Pay You for Life
In the past few years, some high-profile dividend stocks have reduced their payouts, much to the chagrin of investors. As most income seekers want to avoid this fate, they might consider turning to
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in
3 Top Dividend Stocks I Plan to Buy in My Retirement Account in February
I'm loading my retirement account with dividend stocks. The thesis is simple: Dividend stocks have historically outperformed non-dividend payers by more than 2-to-1 over the past 50 years and have